Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.

Show more
Parent Company
Basel, CH
Size (employees)
126,000 (est)+5%
Novartis was founded in 1996 and is headquartered in Basel, CH
Report incorrect company information

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer of Novartis
Steven Baert

Steven Baert

Head of Human Resources of Novartis
Elizabeth Barrett

Elizabeth Barrett

CEO, Novartis Oncology
Bertrand Bodson

Bertrand Bodson

Chief Digital Officer of Novartis
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research (NIBR)
Richard Francis

Richard Francis

CEO, Sandoz
Show more

Novartis Office Locations

Novartis has offices in Basel, New York, East Hanover, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Beijing, CN
14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
Tokyo, JP
Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
East Hanover, US
1 Health Plazam, Bldg. 101
New York, US
230 Park Avenue, 21st Floor
Show all (6)
Report incorrect company information

Novartis Financials and Metrics

Novartis Revenue

Embed Graph
Novartis's revenue was reported to be $48.52 b in FY, 2016 which is a 1.8% decrease from the previous period.

Revenue (FY, 2016)

48.5 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

31 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

6.7 b
USDFY, 2014FY, 2015FY, 2016


53.6 b49.4 b48.5 b

Revenue growth, %


Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b
USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b
USDY, 2016


407.7 k
Show all financial metrics

Novartis Operating Metrics

Y, 2015Y, 2016

Major Approvals (US, EU, JP)

20 16

Patients Reached

972 m965 m

Phase III Trials Products

37 29

Projects Entering Development Pipeline

8 5
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Advanced Accelerator Applications October 30, 2017$3.90 b
AveXis $8.70 b

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 67.1% from Innovative Medicines, 20.9% from Sandoz and 12.0% from Alcon

Report incorrect company information

Novartis Online and Social Media Presence

Embed Graph
Report incorrect company information

Novartis News and Updates

CAR T-Cell Therapy for Multiple Myeloma Market to witness astonishing growth by key players Juno Therapeutics, Kite Pharma, Novartis & Collectis

CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Posted via Industry Today. Follow us on Twitter @IndustryToday

Novartis nabs much-needed new nod for slow-growing breast cancer drug Kisqali

Less than one day after Novartis CEO Vas Narasimhan talked up a potential key approval for lagging breast cancer drug Kisqali, the company has that approval in hand.

Pizotifen Industry : Research Analysis, Development Trends and Survey Report

Pizotifen Industry report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into ,Pizotifen 0.5 mg Tab…
Show more
Report incorrect company information

Novartis Company Life and Culture

Report incorrect company information